Whorwell et al. (University of Manchester, Am J Gastroenterol, 2006, PMID 16863564) demonstrated significant improvement in IBS composite symptom scores within 4 weeks using Bifidobacterium infantis 35624 at 1×10⁸ CFU/day, while Gionchetti et al. (Gastroenterology, 2000, PMID 10930365) measured 85% pouchitis remission maintenance at 9 months with the De Simone Formulation versus 6% in placebo — establishing the clearest published timing benchmarks for probiotic response in UK-relevant clinical populations. This UK evidence guide covers the signs probiotics are working by body system, how long probiotics take to work by use case (IBS, bloating, after antibiotics, women's health), signs they are not working, and features CDS22-formula (8 NCIMB strains, 450 billion CFU, £19.50 per 12-sachet pack, cold-chain delivered by Probiotic.co.uk) as the formulation with the deepest published evidence base available to UK consumers.

Barnes et al. (American Gastroenterological Association, Gastroenterology 2024;166(1):59-85, PMID 38128971) stated that evidence favouring probiotics for preventing pouchitis recurrence is "limited to the De Simone Formulation" — the 8-strain, 450 billion CFU formulation sold in the UK as CDS22-formula (NCIMB-coded strains, cold-chain delivered, £19.50 per 12-sachet pack). This UK evidence guide covers what makes a probiotic "clinical grade," compares Symprove, Alflorex (Precision Biotics, B. infantis 35624), Optibac, Bio-Kult and CDS22-formula by published RCT data, explains the VSL#3/Vivomixx lineage, covers FSA regulatory status, and includes a "signs probiotics are working" timeline — available from Probiotic.co.uk with nationwide cold-chain delivery, regulated under UK food supplement legislation.

Clinical trials on the De Simone Formulation — an 8-strain, 450 billion CFU probiotic blend — demonstrate statistically significant reductions in abdominal bloating and flatulence in IBS patients (Kim et al., Mayo Clinic, 2003 and 2005). This evidence-based guide covers the gut microbiome science behind bloating, strain-specific RCT data, and how UK consumers can identify a clinically researched probiotic for bloating and gas.

Looking for a VSL3 alternative in the UK? The original De Simone Formulation — the 8-strain probiotic blend used in over 80 clinical trials and referenced in ECCO IBD guidelines — was once sold as VSL#3, then as Vivomixx. It is now available in the UK as CDS22-formula. Same strains. Same 450 billion CFU potency. New name. This guide explains the full brand history, the 2016 commercial split, and why CDS22 is the only product in the UK today carrying the original clinically-studied De Simone Formulation.

CDS22 sachets deliver 450 billion CFU across 8 clinically studied De Simone strains versus Optibac Every Day's 5 billion CFU single-strain formula. This comparison covers strain diversity, clinical trial evidence, and cost-per-dose for UK buyers choosing between everyday maintenance and specialist gut support.

The De Simone formulation is the only probiotic referenced in ECCO IBD guidelines for ulcerative colitis and pouchitis, with remission data from multiple randomised controlled trials including Gionchetti 2000 and Mimura 2004. CDS22 contains the original 8 De Simone strains at 450 billion CFU and is the only UK product carrying this clinically studied formulation.

The current VSL#3 formulation was changed following a 2016 US court ruling that separated the product from the original De Simone IP, removing the 8 clinically studied strains. CDS22 is the only UK product containing the original De Simone formulation at 450 billion CFU, with over 80 peer-reviewed trials supporting its use in IBS, ulcerative colitis, and pouchitis.

Clinical trials using the De Simone formulation show statistically significant reductions in IBS symptom scores, with evidence reviewed across IBS-D, IBS-C, and IBS-M subtypes. This UK guide covers strain-specific evidence, CFU thresholds, dietary probiotic sources, and product comparisons including CDS22, Alflorex, and Symprove.

High-CFU multi-strain probiotics have demonstrated greater efficacy than single-strain low-dose products in peer-reviewed IBS and bloating trials, with the De Simone formulation studied at doses between 450 billion and 900 billion CFU. This guide explains the clinical rationale for high-potency formulations and compares UK products including CDS22 against lower-dose alternatives.

Vivomixx was reformulated following a legal dispute over the original De Simone formulation, resulting in Vivomixx Neo — a different strain profile with no independent clinical trial history. CDS22 contains the original 8 De Simone strains at 450 billion CFU, supported by over 80 peer-reviewed trials and referenced in ECCO IBD guidelines.

CDS22 contains the original 8-strain De Simone formulation at 450 billion CFU, with peer-reviewed evidence for IBS symptom reduction, post-antibiotic microbiome recovery, and ulcerative colitis remission. This UK guide compares strain-specific evidence across leading probiotic products and explains why formulation history matters for clinical outcomes.